2. Search Result
Search Result
Results for "

recovery

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

3

Screening Libraries

4

Biochemical Assay Reagents

9

Peptides

2

Inhibitory Antibodies

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14464
    PF-00489791

    PF-489791

    		 Phosphodiesterase (PDE) Metabolic Disease
    PF-00489791 (PF-489791) is a potent inhibitor of phosphodiesterase 5A with IC50 of 1.5 nM. PF-00489791 can enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function .
    PF-00489791
  • HY-15529
    S0859

    		Na+/HCO3- Cotransporter Cardiovascular Disease
    S0859 is a selective, high-affinity generic Na +/HCO3 - transporter (NBC) inhibitor. S0859 reversibly inhibits NBC-mediated intracellular pH (pHi) recovery (Ki=1.7 μM, full inhibition at approximately 30 μM).
    S0859
  • HY-W129456
    Isaxonine

    		Others Neurological Disease
    Isaxonine acts as a modifier of the surface pH of the bilayer . Isaxonine accelerates the rate of peripheral nerve regeneration, stimulate axonal sprouting and promote motor and sensory function recovery . Isaxonine is a neurotrophic agent .
    Isaxonine
  • HY-139708
    NMDA receptor antagonist-3

    		iGluR Neurological Disease
    NMDA receptor antagonist-3, a NMDA receptor antagonist, stands out with a remarkable percentage of recovery (40.0%, at 100 μM) and safe toxicological profile in SH-SY5Y and human adipose mesenchymal stem cells.
    NMDA receptor antagonist-3
  • HY-P2325
    Exoenzyme C3, clostridium botulinum

    		Biochemical Assay Reagents Neurological Disease
    Exoenzyme C3, clostridium botulinum is a promising agent to inactivate RhoA in neurons due to preventing the detrimental effect of active Rho in the recovery of injured neuronal systems. Exoenzyme C3, clostridium botulinum is used for the study of post-traumatic neuro-regeneration .
    Exoenzyme C3, clostridium botulinum
  • HY-44157
    ALS-I

    		Biochemical Assay Reagents Neurological Disease
    ALS-I, an acid-Liable surfactant, is adopted for in-solution enzymatic digestions, can help to solubilize hydrophobic proteins. ALS-I is significantly enhanced peptide recovery for mass spectrometry (MS) mapping in the study of the proteomes of regenerating rat retina and mouse brain .
    ALS-I
  • HY-145686
    AV023

    		Others Inflammation/Immunology
    AV023 is a potent inhibitor of ANKRD22. AV023 promotes the expansion of gastrointestinal mucosal epithelial stem cells and indirectly activates the Wnt classical pathway, which helps the recovery of damaged gastrointestinal mucosal tissues in the body (extracted from patent CN111205231B) .
    AV023
  • HY-108486
    Herbimycin A

    		Bacterial Antibiotic Infection
    Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 v-src and p210 BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.
    Herbimycin A
  • HY-124020
    ß-pBrPh-Glc

    		Others Others
    β-pBrPh-Glc is a small-molecule ice recrystallization inhibitor. β-pBrPh-Glc can control the rate and extent of intracellular ice recrystallization in the nuclei over a broad range of subzero temperatures. β-pBrPh-Glc is an important tool to improve the recovery and function of cryopreserved cells and tissues .
    ß-pBrPh-Glc
  • HY-111793
    NUCC-390

    		CXCR Neurological Disease
    NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046) . NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo .
    NUCC-390
  • HY-111793A
    NUCC-390 dihydrochloride
    2 Publications Verification

    		 CXCR Neurological Disease
    NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046) . NUCC-390 dihydrochloride promotes nerve recovery of function after neurodegeneration in vivo .
    NUCC-390 dihydrochloride
  • HY-157746
    CTPS1-IN-1

    		DNA/RNA Synthesis Inflammation/Immunology Cancer
    CTPS1-IN-1 (compound R80) is a CTPS1 inhibitor. CTPS1-IN-1 has the potential to research cancer (such as promoting vascular injury or surgical recovery) and immune system diseases (such as rejection of transplanted cells and tissues, transplant-related diseases or disorders, allergies, and autoimmune diseases) .
    CTPS1-IN-1
  • HY-107761
    JMV 390-1

    		Others Neurological Disease
    JMV 390-1 (Compound 6a) is a potent multipeptidase inhibitor. JMV 390-1 behaves as a full inhibitor of the major neurotensin (NT)/neuromedin N (NN) degrading enzymes in vitro with IC50 values from 30 to 60 nM. JMV 390-1 increases endogenous recovery of NT and NN from slices of mice hypothalamus depolarized with potassium .
    JMV 390-1
  • HY-118960
    BMS-199264 hydrochloride

    		ATP Synthase Cardiovascular Disease
    BMS-199264 hydrochloride is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 hydrochloride selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 hydrochloride also enhances the recovery of contractile function following reperfusion .
    BMS-199264 hydrochloride
  • HY-150587
    Anti-inflammatory agent 31

    		ERK NF-κB Inflammation/Immunology
    Anti-inflammatory agent 31 (enone 17) is a kind of andrographolide derivatives, is a anti-inflammatory agent. Anti-inflammatory agent 31 inhibits NF-κB activation by upstream blockade of PI3K/Akt and ERK1/2 MAPK activation. Anti-inflammatory agent 31 shows recovery effective of the intracellular GSH levels and protective effect on liver .
    Anti-inflammatory agent 31
  • HY-N2787
    8-​Prenylnaringenin
    1 Publications Verification

    		 Apoptosis Cancer
    8-prenylnaringenin is a prenylflavonoid isolated from hop cones Humulus lupulus, with cytotoxicity. 8-prenylnaringenin has anti-proliferative activity against HCT-116 colon cancer cells via induction of intrinsic and extrinsic pathway-mediated apoptosis. 8-Prenylnaringenin also promotes recovery from immobilization-induced disuse muscle atrophy through activation of the Akt phosphorylation pathway in mice .
    8-​Prenylnaringenin
  • HY-W250310
    L-Arginine α-ketoglutarate

    L-Arginine alpha-ketoglutarate

    		 Biochemical Assay Reagents Others
    L-Arginine α-ketoglutarate, often abbreviated as AAKG, is a dietary supplement that combines arginine L-Arginine and α-ketoglutarate, a key intermediate in the Krebs cycle. L-arginine is a precursor of nitric oxide, which regulates blood flow and promotes vasodilation, while α-ketoglutarate is involved in energy production and protein synthesis. Together, these compounds are thought to support improved muscle recovery, increased endurance, and enhanced athletic performance.
    L-Arginine α-ketoglutarate
  • HY-B0347
    Lacidipine
    1 Publications Verification

    		 Calcium Channel Reactive Oxygen Species Caspase Apoptosis Cardiovascular Disease
    Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI) .
    Lacidipine
  • HY-P9948
    Alemtuzumab

    Campath-IH

    		 Apoptosis Cancer
    Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
    Alemtuzumab
  • HY-W088070A
    Agarose,Low melting point

    		Biochemical Assay Reagents Others
    Agarose,Low melting point is a kind of agarose, a kind of polysaccharide that can be derived from seaweed. It is commonly used in molecular biology and biochemistry to isolate and purify DNA and RNA fragments. Agarose,Low melting point is a low melting point agarose, which is suitable for the recovery of large DNA fragments and enzymatic reactions in gels and other applications. In addition, it has been used in various techniques, such as pulsed field gel electrophoresis and capillary electrophoresis for analyzing genetic material.
    Agarose,Low melting point
  • HY-P5754B
    TAT-NEP1-40 acetate

    		Apoptosis Neurological Disease
    TAT-NEP1-40 acetate is a therapeutic candidate for axonal regeneration and functional recovery after stroke. TAT-NEP1-40 acetate can protect PC12 cells against oxygen and glucose deprivation (OGD) and promote neurite outgrowth. TAT-NEP1-40 acetate protects the brain against ischemia/reperfusion injury through inhibition of neuronal apoptosis. TAT-NEP1-40 acetate can be efficiently delivered into the rat brains .
    TAT-NEP1-40 acetate
  • HY-P5754
    TAT-NEP1-40

    		Apoptosis Neurological Disease
    TAT-NEP1-40 is a BBB-penatrable peptide. TAT-NEP1-40 protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .
    TAT-NEP1-40
  • HY-P5754A
    TAT-NEP1-40 TFA

    		Apoptosis Neurological Disease
    TAT-NEP1-40 TFA is a BBB-penatrable peptide. TAT-NEP1-40 TFA protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 TFA also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 TFA can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .
    TAT-NEP1-40 TFA
  • HY-B0347S1
    Lacidipine-13C8

    		Apoptosis Caspase Calcium Channel Reactive Oxygen Species Cardiovascular Disease
    Lacidipine- 13C8 is the deuterium labeled Lacidipine[1]. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI)[2][3].
    Lacidipine-13C8
  • HY-P5982
    PTPσ Inhibitor, ISP

    		Phosphatase Neurological Disease
    PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .
    PTPσ Inhibitor, ISP
  • HY-18071
    BI-9627
    1 Publications Verification

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .
    BI-9627
  • HY-124619
    GPI-1046

    		FKBP HIV Infection Neurological Disease
    GPI-1046 is a immunophilin ligand without antibiotic action and attenuates ethanol intake in part through the upregulation of glutamate transporter 1 (GLT1) in PFC and NAc-core. GPI-1046 is an analog of FK506, which is an immunophilin ligand that has been shown neuroprotective effects in neurodegenerative disease models . GPI-1046 readily crosses the blood-brain barrier and promotes the regeneration of dopamine (DA) cells in the CNS in association with functional recovery in rodent models . GPI-1046 improves HIV-associated injury of peripheral nerves .
    GPI-1046
  • HY-18071A
    BI-9627 hydrochloride
    1 Publications Verification

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .
    BI-9627 hydrochloride
  • HY-17355
    Pramipexole dihydrochloride
    4 Publications Verification

    		 Dopamine Receptor Neurological Disease
    Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .
    Pramipexole dihydrochloride
  • HY-B0410
    Pramipexole
    4 Publications Verification

    		 Dopamine Receptor Neurological Disease
    Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .
    Pramipexole
  • HY-131997
    2'MeO6MF

    		GABA Receptor Neurological Disease Inflammation/Immunology
    2'MeO6MF is a brain-penetrant positive allosteric modulator at α2β1γ2L and all α1-containing GABAA receptors. 2'MeO6MF also can directly activate α2β2/3 and α2β2/3γ2L GABAA receptors. 2'MeO6MF has anxiolytic and psychomotor stabilizing properties. 2'MeO6MF offers neuroprotection and improved functional recovery and dampens the stroke-induced inflammatory response .
    2'MeO6MF
  • HY-P3801
    [Glp5,(Me)Phe8,Sar9] Substance P (5-11)

    DiMe-C7

    		 Neurokinin Receptor Others Neurological Disease Metabolic Disease
    [Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .
    [Glp5,(Me)Phe8,Sar9] Substance P (5-11)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: